Pharmacology : Anti-emetic drug maropitant induces intestinal motility disorder but not anti-inflammatory action in mice
-
- MIKAWA Shoma
- Department of Veterinary Pharmacology, Graduate School of Agriculture and Life Sciences, The University of Tokyo, Tokyo 113–8657, Japan
-
- YAMAMOTO Shohei
- Department of Veterinary Pharmacology, Graduate School of Agriculture and Life Sciences, The University of Tokyo, Tokyo 113–8657, Japan
-
- ISLAM Md Shafiqul
- Department of Veterinary Pharmacology, Graduate School of Agriculture and Life Sciences, The University of Tokyo, Tokyo 113–8657, Japan
-
- KAJI Noriyuki
- Department of Veterinary Pharmacology, Graduate School of Agriculture and Life Sciences, The University of Tokyo, Tokyo 113–8657, Japan
-
- MURATA Takahisa
- Department of Animal Radiology, Graduate School of Agriculture and Life Sciences, The University of Tokyo, Tokyo 113–8657, Japan
-
- MIZUNO Risuke
- Department of Veterinary Pharmacology, Graduate School of Agriculture and Life Sciences, The University of Tokyo, Tokyo 113–8657, Japan
-
- OZAKI Hiroshi
- Department of Veterinary Pharmacology, Graduate School of Agriculture and Life Sciences, The University of Tokyo, Tokyo 113–8657, Japan
-
- HORI Masatoshi
- Department of Veterinary Pharmacology, Graduate School of Agriculture and Life Sciences, The University of Tokyo, Tokyo 113–8657, Japan
書誌事項
- タイトル別名
-
- Anti-emetic drug maropitant induces intestinal motility disorder but not anti-inflammatory action in mice
この論文をさがす
抄録
Maropitant is a neurokinin 1 receptor (NK1R) antagonist that is clinically used as a new anti-emetic drug for dogs. Substance P (SP) and its receptor NK1R are considered to modulate gastrointestinal peristalsis. In addition, SP works as an inflammatory mediator in gastrointestinal diseases. Aim of this study is to clarify the effects of maropitant on intestinal motility and inflammation in mice. Ex vivo examination of luminal pressure-induced intestinal motility of whole intestine revealed that maropitant (0.1–10 µM) increased frequency of contraction, decreased amplitude of contraction and totally inhibited motility index in a concentration-dependent manner. We measured intestinal transit in vivo by measuring transportation of orally administered luminal content labeled with phenol red. Our results demonstrated that maropitant (10 mg/kg, SC) delayed intestinal transit. Geometric center value was significantly decreased in maropitant-treated mice. Anti-inflammatory effects of maropitant against leukocytes infiltration into the intestinal smooth muscle layer in post-operative ileus (POI) model mice were measured by immunohistochemistry. In POI model mice, a great number of CD68-positive macrophages or MPO-stained neutrophils infiltrated into the inflamed muscle region of the intestine. However, in the maropitant treated mice, the infiltration of leukocytes was not inhibited. The results indicated that maropitant has ability to induce disorder of intestinal motility in mice, but has no anti-inflammatory action in the mouse of a POI model. In conclusion, in mice, maropitant induces disorder of intestinal motility in vivo.
収録刊行物
-
- The Journal of Veterinary Medical Science
-
The Journal of Veterinary Medical Science 77 (10), 1195-1199, 2015
公益社団法人 日本獣医学会
- Tweet
詳細情報 詳細情報について
-
- CRID
- 1390001206429577472
-
- NII論文ID
- 130005107606
-
- NII書誌ID
- AA10796138
-
- ISSN
- 13477439
- 09167250
-
- NDL書誌ID
- 026822083
-
- PubMed
- 25947563
-
- 本文言語コード
- en
-
- データソース種別
-
- JaLC
- NDL
- Crossref
- PubMed
- CiNii Articles
- KAKEN
-
- 抄録ライセンスフラグ
- 使用不可